## **CLAIMS**:

## 1. A compound of formula I:

5 wherein n is 0 or 1;

10

20

X completes a 5- or 6-membered heteroaromatic ring bearing the group Ar as a substituent, and also the group  $R^5$  as a substituent when n is 1;

R<sup>5</sup> represents a hydrocarbon group of 1-5 carbon atoms which is optionally substituted with up to 3 halogen atoms;

Ar represents phenyl or 6-membered heteroaryl, either of which bears 0-3 substituents independently selected from halogen, CF<sub>3</sub>, CHF<sub>2</sub>, CH<sub>2</sub>F, NO<sub>2</sub>, CN, OCF<sub>3</sub>, C<sub>1-6</sub>alkyl and C<sub>1-6</sub>alkoxy;

Y represents a bond or NR<sup>3</sup>;

 $$\rm R^{1}$$  represents H, or when Y represents NR  $^{3},\,R^{1}$  and R  $^{3}$  may together represent - 15  $\,$  CH  $_{2}^{-};$ 

R<sup>2</sup> represents a hydrocarbon group of 1-10 carbon atoms which is optionally substituted with up to 3 halogen atoms, or heteroaryl of 5 or 6 ring atoms optionally bearing up to 3 substituents independently selected from halogen, CF<sub>3</sub>, CHF<sub>2</sub>, CH<sub>2</sub>F, NO<sub>2</sub>, CN, OCF<sub>3</sub>, C<sub>1-6</sub>alkyl and C<sub>1-6</sub>alkoxy; or when Y represents NR<sup>3</sup>, R<sup>2</sup> and R<sup>3</sup> together may complete a heterocyclic ring of up to 6 members which optionally bears up to 3 substituents independently selected from halogen, CF<sub>3</sub>, CHF<sub>2</sub>, CH<sub>2</sub>F, NO<sub>2</sub>, CN, OCF<sub>3</sub>, C<sub>1-6</sub>alkyl and C<sub>1-6</sub>alkoxy;

R<sup>3</sup> represents H or C<sub>1-4</sub>alkyl, or together with R<sup>1</sup> represents -CH<sub>2</sub>-, or together with R<sup>2</sup> completes a heterocyclic ring as defined above; and

25 R<sup>4</sup> represents halogen or C<sub>1-4</sub>alkyl; or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 of formula II:

$$\begin{array}{c|c}
R^{2} & X & (R^{5})_{n} \\
O & Ar \\
O & H
\end{array}$$
II

or a pharmaceutically acceptable salt thereof; where n, X, R<sup>2</sup>, R<sup>4</sup>, R<sup>5</sup> and Ar are as defined in claim 1.

- 3. A compound according to claim 1 wherein Y is a bond and R<sup>2</sup> is hydrocarbon of up to 6 carbon atoms, optionally bearing up to 3 fluorine or chlorine substituents, or 5- or 6-membered heteroaryl which is optionally substituted as defined in claim 1.
- 4. A compound according to claim 1 wherein Y represents NR<sup>3</sup> and either R<sup>3</sup> is H and R<sup>2</sup> represents alkyl, alkenyl, cycloalkyl or cycloalkylalkyl of up to 6 carbon atoms which is optionally substituted with up to 3 fluorine atoms; or R<sup>2</sup> and R<sup>3</sup> complete a heterocyclic ring.
- 5. A compound according to claim 2 wherein R<sup>2</sup> represents alkyl, alkenyl, cycloalkyl or cycloalkylalkyl of up to 6 carbon atoms which is optionally substituted with up to 3 fluorine atoms.
- 6. A compound according to any previous claim wherein X completes a heteroaryl group selected from include 5-aryl-1-methylpyrazol-3-yl, 5-aryloxazol-2-yl, 4-arylpyridin-2-yl, 1-arylimidazol-4-yl, and 1-aryl-[1,2,4]triazol-3-yl, where "aryl" refers to the group Ar as defined in claim 1.
- 7. A pharmaceutical composition comprising a compound according to any previous claim and a pharmaceutically acceptable carrier.
  - 8. A compound according to any of the claims 1-6 for use in a method of treatment of the human body.

- 9. The use of a compound according to any of claims 1-6 for the manufacture of a medicament for treatment or prevention of Alzheimer's disease.
- 5 10. A method of treatment of a subject suffering from or prone to Alzheimer's disease which comprises administering to that subject an effective amount of a compound according to claim 1.